Dynamics and timing of in vivo mutations at Gag residue 242 during primary HIV-1 subtype C infection.
Viral mutations at Gag residue 242 and relevant viral polymorphisms were analyzed in a cohort of 42 individuals with primary HIV-1 subtype C infection using single-genome amplification/sequencing. In HLA-B*57/5801-negative subjects infected with 242N escape variant, reversion to Asn appeared at median (IQR) 103 days (97-213 days) post-seroconversion (p/s) and became dominant at 193 days (170-215 days) p/s. In subjects expressing HLA-B*57/5801 and infected with the wild-type virus, the T242N escape appeared at 203 days (196-231) p/s, reached dominance at 277 days (265-315 days) p/s, and became complete at 323 days (289-373 days) p/s. HLA-B*57/5801-negative subjects infected with 242N escape variant did not show reduced viral load or increased CD4 count. The study highlights the differential selection of T242N escape by HLA-B*57 and B*5801 and suggests that the presence of HLA-B*57/5801-mediated immune pressure is able to control replication of the wild-type virus encoding Thr at Gag residue 242 but fails to suppress the T242N escape variant.
Novitsky
Vladimir
V
Harvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Wang
Rui
R
Margolin
Lauren
L
Baca
Jeannie
J
Moyo
Sikhulile
S
Musonda
Rosemary
R
Essex
M
M
D000328:Adult; D000818:Animals; D005260:Female; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D017354:Point Mutation; D011110:Polymorphism, Genetic; D012641:Selection, Genetic; D013489:Suppression, Genetic; D013997:Time Factors; D055815:Young Adult; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics* / Q000276:immunology*
D015235:HLA-B Antigens; C500126:HLA-B*58:01 antigen; C103707:HLA-B57 antigen; D054301:gag Gene Products, Human Immunodeficiency Virus
AIDS. 1999 Oct 1;13(14):1819-26
10513639
J Virol. 2009 May;83(9):4605-15
19244334
J Virol. 2001 Dec;75(24):11983-91
11711588
Science. 1996 Jul 26;273(5274):415-6
8677432
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
18490657
PLoS One. 2008 Jan 09;3(1):e1424
18183304
AIDS Care. 2008 Aug;20(7):806-11
18608056
J Virol. 2002 Mar;76(5):2298-305
11836408
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):265-72
19525854
Nat Genet. 2004 Jun;36(6):565-74
15167933
Nature. 2009 Apr 2;458(7238):641-5
19242411
J Virol. 2008 Sep;82(17):8548-59
18596105
AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8
8959245
J Virol. 2004 Apr;78(7):3233-43
15016844
J Virol. 2003 Jan;77(2):882-90
12502804
J Virol. 2002 Jun;76(11):5435-51
11991972
PLoS Pathog. 2008 Mar 21;4(3):e1000033
18369479
PLoS One. 2009 Nov 05;4(11):e7727
19890401
AIDS. 2003 Sep 5;17(13):1871-9
12960819
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):65-76
19295336
J Forensic Sci. 2002 Jul;47(4):811-8
12136989
J Exp Med. 2009 Apr 13;206(4):909-21
19307327
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14
10694578
J Gen Virol. 1998 Sep;79 ( Pt 9):2191-201
9747728
Nat Med. 2007 Jan;13(1):46-53
17173051
Nat Med. 2004 Mar;10(3):282-9
14770175
J Virol. 2009 Oct;83(19):10234-44
19605475
J Infect Dis. 2005 Nov 1;192(9):1588-96
16206073
J Clin Microbiol. 2005 Jan;43(1):406-13
15635002
Virology. 2009 Jan 5;383(1):47-59
18973914
Nat Med. 1996 Apr;2(4):405-11
8597949
PLoS One. 2009;4(1):e4188
19142234
J Virol. 2006 Mar;80(6):3122-5
16501126
J Virol. 2007 Mar;81(5):2440-8
17182686
J Immunol. 2002 Dec 1;169(11):6376-85
12444145
J Virol. 2009 Mar;83(6):2460-8
19109381
J Virol. 2006 Apr;80(7):3617-23
16537629
AIDS. 2008 Jul 11;22(11):1277-86
18580606
Virology. 2006 May 25;349(1):142-55
16519915
Bioinformatics. 2000 Apr;16(4):400-1
10869039
Clin Immunol. 2009 May;131(2):277-87
19135418
J Virol. 2007 Aug;81(15):8346-51
17507468
J Exp Med. 2008 May 12;205(5):1009-17
18426987
AIDS. 2003 Dec 5;17(18):2581-91
14685052